Point-of-Care Microfluidic Platform for Detecting Traumatic Brain Injury (TBI)


This device is a first-of-its-kind diagnostic that uses microfluidics to measure FDA-approved biomarker concentrations in whole blood and plasma to detect TBI.

Value Proposition

TBI patients are usually in a coma, which limits clinicians' ability to monitor responses to treatment in real-time. This device solves that dilemma and is capable of real-time measurement of biofluid markers of TBI, enabling objective and personalized assessment of TBI status and monitoring of patient response to targeted TBI pharmacotherapy.

Competitive Advantage

  • First-to-market opportunity for real-time point-of-care and point-of-injury monitoring

  • Significantly smaller and more cost-effective than existing capabilities in the market

  • Allows for greater precision in determining need for more advanced imaging/diagnostics and as a means to monitor patient trajectory to guide treatments

  • Usable in austere environments

Unique Features

  • Customizable multiplexing of biomarkers

  • Handheld

  • Sends results directly to a smartphone

Principal Investigators
Fred Korley, MD, PhD
Mark Burns, PhD

Licensing Manager
Jeremy Nelson

Intellectual Property
Invention Disclosure #2019-411
Patent Issued #US20200230603A1, US10845284

Solution Sheet
Download Solution Sheet

Photo courtesy of project team

MARKET OPPORTUNITY
Hospitals field nearly a quarter of a million TBI patients yearly, and less than 70% survive. Currently, there are no diagnostics for monitoring response to neuroprotective treatments in severely injured TBI patients. Real-time monitoring via microfluidics will provide clinicians with objective data on the amount of brain cells that are dying and determine whether the treatment being administered is decreasing that number.

The Point-of-Care Microfluidic Platform for Detecting TBI is currently available for optioning while the team works to reduce the size of the device.
Please contact the Licensing Manager, Jeremy Nelson, for more information.

Funding History

$581,617 in non-dilutive funding

  • 2017 $94,693 Massey Grand Challenge

  • 2018 $115,800 Massey Grand Challenge

  • 2019 $107,996 Massey Grand Challenge

  • 2019 $40,000 Schwabauer Accelerator Award

  • 2020 $183,128 Massey Grand Challenge

  • 2020 $40,000 Schwabauer Accelerator Award

  • Substantial additional departmental, school and center based support

Completed Milestones

  • Developed prototype of microfluidic chip

  • Three custom immunoassays for TBI biomarkers of interest

  • Proof-of-concept on-chip multiplexing of three TBI biomarkers

  • Preliminary system validation with clinical serum samples

Next Steps

  • Develop a ruggedized portable detection module

  • Test the system under extreme conditions (high temperature and humidity)

  • Customer discovery

  • Strategic partner discovery

  • License the technology to an industry partner.


Funding Organizations

Publications

Lab on a Chip, 2020

Media Coverage

Weil DoD Funding, 2022